salvinorin a
Small moleculeexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00996411)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Kappa opioid receptorAGONIST
OPRK1 agonist
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C- Mol. weight
- 432.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL445332 ↗
Also known as
- salvinorin a
- salvinorin a
- salvinorin a
- salvinorin-a
- salvinorin-a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03418714 | Phase 1/Phase 2 (Phase 2) | Dec 14, 2017 | Johns Hopkins University, National Institute on Drug Abuse (NIDA) |
| NCT02033707 | Phase 1 | Apr 1, 2014 | Johns Hopkins University |
| NCT01149824 | N/A | Jun 1, 2009 | University of California, San Francisco |
| NCT00700596 | Phase 1 | Jan 1, 2009 | Brain & Behavior Research Foundation, Yale University |
| NCT00996411 | Phase 1 | Nov 1, 2008 | Johns Hopkins University, National Institute on Drug Abuse (NIDA) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 3 | 3 | 2 | 2008 |
| National Institute on Drug Abuse (NIDA) | Government | 2 | 0 | 2 | 2008 |
| Brain & Behavior Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2009 |
5 organizations
Page 1 / 1